Latest WatchPAT innovation improves patient comfort and simplifies physician workflow

CAESAREA, Israel, March 20, 2019 (GLOBE NEWSWIRE) -- Itamar Medical Ltd. (Nasdaq & TASE: ITMR), a company that develops, manufactures and markets non-invasive diagnostic medical devices for sleep apnea with a focus on the cardiology market, today announced the launch of WatchPAT 300, the next generation WatchPAT system for home sleep apnea testing. WatchPAT 300 includes several advances that are designed to enhance both patients’ WatchPAT experience as well as provide physicians with a trusted and cost-effective method for rapid, scalable and effective diagnosis of sleep apnea.

“Sleep apnea has reached epidemic levels and is estimated to affect 25 percent of adults worldwide,” said Gilad Glick, President and CEO of Itamar Medical. “This has significant health and economic implications, as half of all patients with cardiovascular disease are believed to suffer from sleep apnea and the total cost of unmanaged obstructive sleep apnea is $150 billion each year in the United States alone. Addressing the challenge of efficiently and cost-effectively diagnosing the millions of patients with undiagnosed sleep apnea requires a simple, accurate and scalable modality. We believe that WatchPAT 300 – which demonstrates Itamar Medical’s continued commitment to innovation focused on meeting the needs of patients, health systems, payers and physicians – can play a critical role in solving this challenge.”

WatchPAT 300 utilizes peripheral arterial tone and other signals to calculate True Sleep Time and Complete Sleep Architecture to accurately and reliably diagnose both obstructive and central sleep apnea.

WatchPAT 300 has an intuitive and more comfortable design with three points of contact and without cumbersome nasal canula or chest belts to ensure patient ease of use. It is based on the peripheral arterial tone signal (PAT) and uses its advanced actigraphy to differentiate between wake and sleep periods to calculate true sleep time. WatchPAT 300 also uses the PAT amplitude and pulse rate to differentiate between non-rapid eye movement (REM) and REM sleep. It also provides clinically validated sleep architecture, based on sleep stages, including sleep efficiency, sleep latency and REM latency. Its total sleep time reduces the risk of misdiagnosis and misclassification that has been reported to be 20 percent in studies using total recording time. WatchPAT 300 also includes a Central+ module, which enables specific identification for Central Sleep Apnea events. Its one-stop preparation comes with a significantly faster download and automated study preparation time to improve workflow.

WatchPAT 300 was granted 510(k) clearance by the U.S. Food and Drug Administration on August 17, 2018 and will gradually replace the current WatchPAT 200 platform and will be presented at SLEEP 2019 on June 8-12 in San Antonio, TX (booth # 916). WatchPAT 300 will be compatible with zzzPATTM software and CloudPATTM, Itamar Medical’s cloud-based IT solution for convenient sleep diagnosis and secure patient data transfers to streamline workflow.

About Itamar Medical Ltd.

Itamar Medical is engaged in research, development, sales and marketing of non-invasive medical devices for the diagnosis of respiratory sleep disorders with a focus on the cardiology market. The Company offers a Total Sleep Solution™ to help physicians provide comprehensive sleep apnea management in a variety of clinical environments to optimize patient care and reduce healthcare costs. Its flagship PAT-based product, the WatchPAT™ device, is a home-use diagnostic device for sleep breathing disorders. It also offers the EndoPAT™ system, an FDA-approved device to test endothelial dysfunction and to evaluate the risk of heart disease and other cardiovascular diseases. Itamar Medical is a public company traded on the Nasdaq and on the Tel Aviv Stock Exchange and is based in Caesarea, Israel with U.S. headquarters based in Atlanta, GA. For additional information visit www.itamar-medical.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of applicable securities laws. Statements preceded by, followed by, or that otherwise include the words "believes", "expects", "anticipates", "intends", "estimates", "plans", and similar expressions or future or conditional verbs such as "will", "should", "would", "may" and "could" are generally forward-looking in nature and not historical facts. For example, when we discuss growing appreciation within the cardiology community of the role of WatchPAT or when we discuss the benefits of the WatchPAT 300 and it gradually replacing the WatchPAT 200, we are using forward-looking statements. Because such statements deal with future events, they are subject to various risks, uncertainties and assumptions, including events and circumstances out of Itamar Medical's control and actual results, expressed or implied by such forward-looking statements, could differ materially from Itamar Medical's current expectations. Factors that could cause or contribute to such differences include, but are not limited to, risks, uncertainties and assumptions discussed from time to time by Itamar Medical in reports filed with, or furnished to, the Israel Securities Authority and the U.S. Securities and Exchange Commission. Except as otherwise required by law, Itamar Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.

Contacts:

David Carey
Lazar Partners Ltd.
212-867-1762

Eran Gabay
Partner
Galbert-Kahana Investor Relations and Public Relations
+972-54-2467378

* The contents of any website or hyperlinks mentioned in this press release are for informational purposes and the contents thereof are not part of this press release.

A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/e17564f2-ef84-4dde-8fa4-337060bd2354